Syfovre Injection, Solution
NDC Package 73606-020-12

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Syfovre (pegcetacoplan) injection is sYFOVRE is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). This formulation utilizes a injection, solution delivery system. Marketed by Apellis Pharmaceuticals, Inc., this product is identified by NDC 73606-020 and is authorized under FDA application NDA217171.

Identification & Billing

NDC Package Code
73606-020-12
Package Description
1 VIAL, GLASS in 1 CARTON / 3 mL in 1 VIAL, GLASS
Product Code
73606-020
11-Digit Billing Format
73606002012
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Syfovre
Non-Proprietary Name
Pegcetacoplan
Substance Name
Pegcetacoplan
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Intravitreal - Administration within the vitreous body of the eye.
Active Ingredient(s)
PEGCETACOPLAN 15 mg/.1mL
Pharmacologic Class
Usage Information
SYFOVRE is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Regulatory & Marketing

Labeler Name
Apellis Pharmaceuticals, Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA217171
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
02-17-2023
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
Yes

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (73606-020). Click a package code to view its specific billing and regulatory data.

73606-020-01
1 VIAL, GLASS in 1 CARTON / 3 mL in 1 VIAL, GLASS
73606-020-02
1 VIAL, GLASS in 1 CARTON / 3 mL in 1 VIAL, GLASS
73606-020-11
1 VIAL, GLASS in 1 CARTON / 3 mL in 1 VIAL, GLASS

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 73606-020-12 identifies a specific commercial package of 1 vial, glass in 1 carton / 3 ml in 1 vial, glass of Syfovre, a human prescription drug labeled by Apellis Pharmaceuticals, Inc.. This injection, solution is formulated for intravitreal use and contains pegcetacoplan as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Apellis Pharmaceuticals, Inc. on February 17, 2023. The current certification is valid through December 31, 2026.

How is this Apellis Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 73606002012. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
73606-020-12
11-Digit CMS (5-4-2)
73606-0020-12

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.